John Sourbeer
Stock Analyst at UBS
(0.84)
# 4,032
Out of 5,115 analysts
44
Total ratings
38.1%
Success rate
-14.35%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $9.51 | +31.44% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $144.81 | -17.13% | 6 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $231.12 | +53.60% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $46 → $48 | $53.67 | -11.27% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $180.25 | +33.15% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $15.58 | +50.83% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $27.17 | +65.62% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $2.26 | -11.50% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $582.48 | -17.59% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $44.29 | +130.30% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $20.20 | +147.52% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $109.30 | +17.11% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $9.51
Upside: +31.44%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $144.81
Upside: -17.13%
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $231.12
Upside: +53.60%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $46 → $48
Current: $53.67
Upside: -11.27%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $180.25
Upside: +33.15%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $15.58
Upside: +50.83%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $27.17
Upside: +65.62%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $2.26
Upside: -11.50%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $582.48
Upside: -17.59%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $44.29
Upside: +130.30%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $20.20
Upside: +147.52%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $109.30
Upside: +17.11%